ClinicalTrials.gg
Active, not recruitingNCT04586010FENhanceUpdated Sep 21, 2026

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

A Phase 3 interventional study of Fenebrutinib and Teriflunomide in Relapsing Multiple Sclerosis, sponsored by Hoffmann-La Roche. Active, not recruiting at 158 sites in 23 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
746
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Multiple Sclerosis by Hoffmann-La Roche — 6 open to participants now, 17 under way, 7 of them phase 3. Multiple Sclerosis · Hoffmann-La Roche.

Enrollment
9th of 31
746 · median 134
Started
2021
with 3 others
Phase 3
11 of 35
2 open now
Primary completion
2026-01
later than 5 of 16 live
Registered
18th of 35
by date

Among the 35 studies in Multiple Sclerosis by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2021, is one of 11 in phase 3, reaches primary completion later than 5 of the 16 other live ones, and was the 18th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

6 of the 35 studies in Multiple Sclerosis by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Multiple Sclerosis by Hoffmann-La Roche, or all of them as a file.
02

Study summary

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Expanded Disability Status Scale (EDSS) score of 0 - 5.5 at screening
  • A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria
  • Ability to complete the 9-Hole Peg Test (9-HPT) for each hand in \< 240 seconds
  • Ability to perform the Timed 25-Foot Walk Test (T25FWT) in \< 150 seconds
  • For female participants of : agreement to remain abstinent (refrain from heterosexual intercourse) or use measures, and refrain from donating eggs
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm

OLE Inclusion Criteria:

  • Completed the DBT phase of the study (remaining on study treatment; no other disease-modifying therapy (DMT) administered) and who, in the opinion of the investigator, may benefit from treatment with fenebrutinib
  • Participants randomized to the teriflunomide treatment arm during the DBT phase must undergo the accelerated teriflunomide elimination procedure (ATEP) prior to the first administration of open-label fenebrutinib
  • For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • Disease duration of > 10 years from the onset of symptoms and an EDSS score at screening \< 2.0
  • Female participants who are pregnant or breastfeeding, or intending to become pregnant
  • Male participants who intend to father a child during the study
  • A diagnosis of primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (SPMS)
  • Any known or suspected active infection at screening, including but not limited to a positive screening test for (HBV) and (HCV), an active or latent or inadequately treated infection with tuberculosis (TB), a confirmed or suspected progressive multifocal leukoencephalopathy (PML)
  • History of cancer including hematologic and solid tumors within 10 years of screening
  • Known presence of other neurological disorders, that could interfere with the diagnosis of MS or assessments of efficacy or safety during the study and cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal (GI) disease
  • Rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
  • Hypoproteinemia
  • Acute liver disease
  • Chronic liver disease unless considered stable for > 6 months
  • Presence of cirrhosis ( Class A, B, or C) or Gilbert's Syndrome
  • Participants with significantly impaired bone marrow function or significant anemia, leukopenia, neutropenia or thrombocytopenia
  • Any concomitant disease that may require chronic treatment with systemic or during the course of the study
  • History of alcohol or other drug abuse within 12 months prior to screening
  • History of or currently active primary or secondary (non-drug-related) immunodeficiency, including known history of (HIV) infection
  • Inability to complete an MRI scan
  • Adrenocorticotropic hormone or systemic corticosteroid therapy within 4 weeks prior to screening (inhaled and topical corticosteroids are allowed)
  • Receipt of a within 6 weeks prior to randomization
  • Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate

OLE Exclusion Criteria:

  • Acute liver disease
  • Chronic liver disease unless considered stable for > 6 months
  • Cirrhosis (Child-Pugh Class A, B, or C)
  • Gilbert's syndrome
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
746 participants (actual)

Study arms

  • Experimental
    Fenebrutinib

    Participants will receive oral (PO) fenebrutinib, with teriflunomide-matching placebo.

    Drug: Fenebrutinib · Drug: Placebo

  • Active comparator
    Teriflunomide

    Participants will receive PO teriflunomide, with fenebrutinib-matching placebo in a blinded fashion.

    Drug: Teriflunomide · Drug: Placebo

Interventions

  • Participants will receive fenebrutinib.

  • Participants will receive teriflunomide.

  • DrugPlacebo

    Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.

06

What researchers measure

Primary outcomes

  1. Annualized Relapse Rate (ARR)

    Time frame: Minimum of 96 weeks

Secondary outcomes

  1. Time to Onset of Composite 12-week Confirmed Disability Progression (cCDP12)

    Time frame: Minimum of 96 weeks

  2. Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)

    Time frame: Minimum of 96 weeks

  3. Time to Onset of 12-week Confirmed Disability Progression (CDP12)

    Time frame: Minimum of 96 weeks

  4. Time to Onset of 24-week Confirmed Disability Progression (CDP24)

    Time frame: Minimum of 96 weeks

  5. Total Number of T1 Gadolinium Enhancing (Gd+) Lesions, New and/or Enlarging T2-weighted Lesions, as Detected by Magnetic Resonance Imaging (MRI)

    Time frame: Baseline, Weeks 12, 24, 48 and 96

  6. Percentage Change in Total Brain Volume From Week 24 as Assessed by MRI

    Time frame: From Week 24 to Week 96

  7. Change in Participant-reported Physical Impacts of Multiple Sclerosis (MS), as Measured by the Multiple Sclerosis Impact Scale (29-item), Version 2 (MSIS-29) Physical Scale

    Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96

  8. Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT) Score

    Time frame: Minimum of 96 weeks

  9. Percent Change From Baseline to Week 48 in the Concentration of Blood Neurofilament Light Chain (NfL)

    Time frame: Baseline, Week 48

  10. Time to Onset of Composite 12-week Confirmed Progression Independent of Relapse Activity (cPIRA12)

    Time frame: Minimum of 96 weeks

  11. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to 4.5 years

  12. Plasma Concentrations of Fenebrutinib at Specified Timepoints

    Time frame: Up to 4.5 years

07

Study locations

158 sites

Showing the first 100 of 158 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jan 2026, 58 months.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 58 months is above that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2020
First posted
Oct 14, 2020
StartActual
Mar 17, 2021
Primary completionActual
Jan 27, 2026
CompletionEst.
Nov 30, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04586010
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 14, 2020
Start date
Mar 17, 2021
Primary completion
Jan 27, 2026
Completion
Nov 30, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenebrutinib

Start the discussion